Incyte Aktie
| 72,52USD | -0,70USD | -0,96% |
WKN: 896133 / ISIN: US45337C1027
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98,39 |
| Baker Bros. Advisors LP | 16,09 |
| Baker Bros. Advisors LP | 15,96 |
| Vanguard Group, Inc. (Subfiler) | 10,21 |
| Dodge & Cox | 8,35 |
| Dodge & Cox | 7,93 |
| RBC Global Asset Management (UK) Ltd. | 5,69 |
| SSgA Funds Management, Inc. | 5,48 |
| State Street Corp. | 5,48 |
| Dodge & Cox Stock Fund | 5,04 |
| BlackRock Fund Advisors | 4,28 |
| Vanguard Total Stock Market ETF | 2,69 |
| Renaissance Technologies LLC | 2,34 |
| Vanguard 500 Index Fund | 2,20 |
| BlackRock Institutional Trust Co. NA | 2,07 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 456 | 1 773 | 2 094 | 2 324 | 2 524 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,48 | 1,50 | 1,43 | 1,46 | 1,46 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 481 | 2 360 | 3 119 | 4 093 | 4 645 |
| Summe Anlagevermögen | 945 | 1 224 | 1 855 | 1 791 | 2 177 |
| Summe Aktiva | 3 427 | 3 584 | 4 974 | 5 884 | 6 822 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 72 | 62 | 60 | 56 | 53 |
| Summe Fremdkapital | 828 | 972 | 1 204 | 1 513 | 1 632 |
| Summe Eigenkapital | 2 598 | 2 611 | 3 770 | 4 370 | 5 190 |
| Summe Passiva | 3 427 | 3 584 | 4 974 | 5 884 | 6 822 |
Adresse
| 1801 Augustine Cut-Off, 19803 Wilmington | |
| Telefon | +1 (302) 498-6700 |
| Internet | http://www.incyte.com |
Management
|
Barry P Flannelly
Executive VP & General Manager-North America |
|
Benjamin J. Strain
Head-Investor Relations |
|
Christiana Stamoulis
Chief Financial Officer & Executive Vice President |
|
Edmund P. Harrigan
Independent Director |
|
Herve Hoppenot
Chairman, President & Chief Executive Officer |
|
Jacqualyn A. Fouse
Independent Director |
|
Jean-Jacques Bienaimé
Independent Director |
|
Julian Charles Baker
Lead Independent Director |
|
Katherine A. High
Independent Director |
|
Keith Mikkelson
Executive Director-Business Development |
|
Lothar H. Finke
Group Vice President & General Manager |
|
Michael Morrissey
Executive VP & Head-Global Technical Operations |
|
Otis W. Brawley
Independent Director |
|
Pablo J. Cagnoni
President-Research & Development |
|
Paul J. Clancy
Independent Director |
|
Paula J. Swain
Executive Vice President-Human Resources |
|
Peter Langmuir
Vice President-Oncology Drug Development |
|
Sheila A. Denton
Secretary, Executive VP & General Counsel |
|
Steven H. Stein
Chief Medical Officer & Executive Vice President |
|
Susanne Antonie Schaffert
Independent Director |
|
Thomas Tray
Chief Accounting Officer & Vice President-Finance |
|
Vijay Iyengar
EVP, Head-Global Medical Affairs & Product |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
